Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Harriette Van Spall , Isabelle Mahé Added: 1 year ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the… View more
Dr Michael D Stubblefield is Medical Director for Cancer Rehabilitation at Kessler Institute for Rehabilitation, National Medical Director for Select Medical’s ReVital Cancer Rehabilitation Program and National Medical Director for Complex Medical Rehabilitation for Select Medical’s Inpatient Rehabilitation Hospital Division. He is President of the International Cancer Rehabilitation Foundation… View more